Quick Answer
NEKTAR THERAPEUTICS reported Net Income of -$164.08 million for fiscal year 2025.
NEKTAR THERAPEUTICS Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$164.08M | -37.9% |
| 2024 | -$118.96M | +56.9% |
| 2023 | -$276.06M | +25.0% |
| 2022 | -$368.20M | +29.7% |
| 2021 | -$523.84M | -17.9% |
| 2020 | -$444.44M | -0.9% |
| 2019 | -$440.67M | -164.7% |
| 2018 | $681.31M | +804.6% |
| 2017 | -$96.69M | +37.0% |
| 2016 | -$153.52M | -89.1% |
| 2015 | -$81.18M | -50.6% |
| 2014 | -$53.92M | +66.7% |
| 2013 | -$162.01M | +5.7% |
| 2012 | -$171.85M | -28.3% |
| 2011 | -$133.98M | -253.1% |
| 2010 | -$37.94M | +63.0% |
| 2009 | -$102.52M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.52M | +4.1% | +14.6% |
| June 30, 2025 | -$41.59M | +20.6% | +18.3% |
| March 31, 2025 | -$50.88M | -38.3% | -37.3% |
| September 30, 2024 | -$37.06M | +19.2% | +29.2% |
| June 30, 2024 | -$52.36M | -2.4% | -42.3% |
| March 31, 2024 | -$36.80M | +73.1% | +19.7% |
| September 30, 2023 | -$45.84M | +22.4% | +10.3% |
| June 30, 2023 | -$51.12M | +67.9% | +62.7% |
- NEKTAR THERAPEUTICS showed a decrease of -37.9% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, NEKTAR THERAPEUTICS’s net income has declined by 60.0% (from -$102.52 million to -$164.08 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: